The prevalence of CAN among diabetes patients ranges from 20 to 60%
John's Great experience top to bottom
L., and Borum, P
For functional medicine practitioners and researchers interested in this area, understanding what the evidence actually supports versus what remains speculative is the critical starting point
Typical Treatment Timeline First 12 Months Hair shedding may stabilize Hair growth cycle begins transitioning 34 Months Early improvements in thickness and density Reduced shedding 6 Months Noticeably fuller-looking hair for many patients 912 Months Continued improvement with consistent use Individual results vary and depend on factors such as age, genetics, hormone levels, nutrition, and treatment adherence

Multiple cardiovascular outcome trials (ELIXAlixisenatide, LEADERliraglutide, SUSTAIN-6semaglutide, EXSCELexenatide, Harmony Outcomesalbiglutide, REWINDdulaglutide, and PIONEER-6oral semaglutide) have reported, to a greater or lesser extent, improvements in cardiovascular outcomes, with a systematic review and meta-analysis of these trials involving a combined total of 56,004 participants showing that these drugs as a class reduced major adverse cardiovascular events by 12%, death from cardiovascular causes by 12%, fatal or nonfatal stroke by 16%, and fatal or nonfatal myocardial infarction by 9%